Valuation: Axogen, Inc.

Market Cap 2.09B 1.83B 1.7B 1.56B 2.95B 202B 2.99B 20.29B 7.94B 98.85B 7.86B 7.69B 341B P/E 2026 *
-101x
P/E 2027 * 255x
Enterprise Value 2.09B 1.83B 1.7B 1.56B 2.95B 202B 2.99B 20.29B 7.94B 98.85B 7.86B 7.69B 341B EV / Sales 2026 *
7.73x
EV / Sales 2027 * 6.58x
Free-Float
96.5%
Yield 2026 *
-
Yield 2027 * -
1 day-2.21%
1 week+1.68%
Current month-14.77%
1 month-12.41%
3 months+6.41%
6 months+23.03%
Current year+20.29%
1 week 38.44
Extreme 38.44
40.87
1 month 38.23
Extreme 38.23
46.95
Current year 27.54
Extreme 27.54
46.95
1 year 12.38
Extreme 12.385
46.95
3 years 3.45
Extreme 3.45
46.95
5 years 3.45
Extreme 3.45
46.95
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 09/08/2024
Director of Finance/CFO 42 12/05/2025
Chief Operating Officer 65 10/01/2025
Director TitleAgeSince
Director/Board Member 65 01/09/2016
Director/Board Member 58 15/05/2019
Chairman 70 09/08/2024
Date Insider Type Main position Quantity % Market Cap.
6/24/26 A Free

Director

4,392 0.0083%
6/24/26 A Free

Director

4,392 0.0083%
6/24/26 A Free

Chairman

5,579 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
-2.21%+1.68%+213.96%+349.43% 2.14B
+0.57%-1.65%+23.11%-6.36% 195B
+0.07%-10.78%-5.67%-29.99% 126B
-2.68%-12.41%-33.33%+1.20% 124B
-0.51%-0.16%-58.35%-19.17% 64.2B
-0.21%-3.32%+10.58%-8.86% 48.68B
+0.17%-0.52%-24.32%-32.66% 43.83B
+0.45%-0.93%+14.86%+4.58% 37.52B
+0.89%-1.09%+29.00%+28.44% 36.09B
-0.86%+1.99%+87.07%+0.20% 29.13B
Average -0.14%-2.88%+25.69%+28.68% 70.59B
Weighted average by Cap. +0.19%-5.01%-0.07%-8.50%

Financials

2026 *2027 *
Net sales 271M 237M 220M 202M 382M 26.14B 387M 2.62B 1.03B 12.79B 1.02B 995M 44.18B 318M 279M 259M 238M 448M 30.73B 455M 3.09B 1.21B 15.03B 1.2B 1.17B 51.94B
Net income -21.17M -18.55M -17.22M -15.82M -29.82M -2.04B -30.26M -205M -80.29M -1B -79.47M -77.76M -3.45B 8.06M 7.06M 6.55M 6.02M 11.35M 777M 11.51M 78.07M 30.56M 380M 30.24M 29.59M 1.31B
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
22/07/26 $39.37 -2.21% 982,991
21/07/26 $40.26 +1.98% 1,242,752
20/07/26 $39.48 -0.93% 1,063,952
17/07/26 $39.85 +0.19% 1,200,575
16/07/26 $39.78 +2.72% 1,323,806
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
39.37USD
Average target price
50.78USD
Spread / Average Target
+28.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock